Prospect: information for the user

Jalra 50mg tablets

vildagliptina

Read this prospect carefully before starting to take this medicine, as it contains important information for you.

• Keep this prospect, as you may need to read it again.
• If you have any doubts, consult your doctor, pharmacist, or nurse.
• This medicine has been prescribed only for you, and you should not give it to other people even if they have the same symptoms as you, as it may harm them.
• If you experience any adverse effects, consult your doctor, pharmacist, or nurse, even if they do not appear in this prospect. See section4.

1.What is Jalra and how it is used

2.What you need to know before starting to takeJalra

3.How to take Jalra

4.Possible adverse effects

5.Storage of Jalra

6.Contents of the package and additional information

The active ingredient of Jalra, vildagliptina, belongs to a group of medications called «oral antidiabetics».

Jalra is used to treat adult patients with type 2 diabetes when the diabetes cannot be controlled solely by diet and exercise. It helps control blood sugar levels. Your doctor will prescribe Jalra alone or in combination with other antidiabetic medications you are already taking if these are not effective enough to control diabetes.

Type 2 diabetes appears if the body does not produce enough insulin or if the insulin produced does not function properly. It can also appear if the body produces too much glucagon.

Insulin is a substance that helps reduce blood sugar levels, especially after meals. Glucagon is a substance that promotes sugar production by the liver and increases blood sugar levels. Both substances are produced in the pancreas.

How Jalra works

Jalra stimulates the pancreas to produce more insulin and less glucagon. This helps control blood sugar levels.This medication has been shown to reduce blood sugar levels, which will help prevent diabetes complications.

Although you start taking this medication for your diabetes, it is essential that you continue with the diet and/or exercise that have been recommended.

Do not take Jalra

• If you are allergic to vildagliptin or any of the other components of this medication (listed in section6). If you think you could be allergic to vildagliptin or any other component of Jalra, do not take this medication and consult your doctor.

Warnings and precautions

Consult your doctor, pharmacist, or nurse before starting to take Jalra

• If you have type1 diabetes (i.e., your body does not produce insulin) or if you have a condition called diabetic ketoacidosis.
• If you are taking a diabetes medication known as a sulfonylurea (your doctor may want to reduce your sulfonylurea dose when taking Jalra together with it to avoid low blood glucose [hypoglycemia]).
• If you have moderate or severe kidney disease (you will need to take a lower dose of Jalra).
• If you are undergoing dialysis.
• If you have liver disease.
• If you have heart failure.
• Ifyou have or have had pancreatitis.

If you have previously taken vildagliptin but had to stop taking it due to liver disease, do not take this medication.

Skin lesions are common complications of diabetes. Follow the recommendations of your doctor or nurse for skin and foot care, paying special attention to the appearance of blisters or ulcers while taking Jalra. If this occurs, you should consult your doctor as soon as possible.

Liver function tests should be performed before starting treatment with Jalra, at three-month intervals during the first year, and periodically thereafter. This is done to detect as soon as possible any signs indicating an increase in liver enzymes (transaminases).

Children and adolescents

The administration of Jalra is not recommended in children and adolescents under 18 years of age.

Use of Jalra with other medications

Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.

Your doctor may change your Jalra dose if you are taking other medications such as:

• Thiazides or other diuretics (also known as urine medications)
• Corticosteroids (usually used to treat inflammation)
• Thyroid medications
• Certain medications that affect the nervous system.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.

You should not use Jalra during pregnancy. It is unknown whether Jalra passes into breast milk. Do not take Jalra if you are breastfeeding or plan to breastfeed.

Driving and operating machinery

If you feel dizzy while taking Jalra, do not drive or operate tools or machinery.

Jalra contains lactose

Jalra contains lactose (milk sugar). If your doctor has told you that you have a certain sugar intolerance, consult with him before taking this medication.

Jalra contains sodium

This medication contains less than 1mmol of sodium (23mg) per tablet; this is essentially “sodium-free”.

Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.

How much to take and when

The dose of Jalra that each person should take varies depending on their condition. Your doctor will indicate exactly the number of Jalra tablets you should take. The maximum daily dose is 100 mg.

The recommended dose of Jalra is:

• 50 mg once a day in the morning, if you are taking Jalra along with another medication known as a sulfonylurea.
• 100 mg per day in two doses of 50 mg in the morning and evening if you are taking Jalra alone, with another medication known as metformin or a glitazone, with a combination of metformin and a sulfonylurea, or with insulin.
• 50 mg per day in the morning if you have moderate or severe kidney disease or if you are undergoing dialysis.

How to take Jalra

• Swallow the tablet whole with a little water.

Duration of Jalra treatment

• Take Jalra every day as your doctor indicates. You may need to follow this treatment for a long period of time.
• Your doctor will perform regular checks to ensure that the treatment is having the desired effect.

If you take more Jalra than you should

If you have taken too many Jalra tablets, or if someone else has taken your medication,consult your doctor immediately.You may need medical attention. If you need to visit a doctor or go to the nearest hospital, bring the packaging with you.

If you forget to take Jalra

If you forget to take a dose of this medication, take it as soon as you remember. Then take the next dose at your usual time. If it is almost time for your next dose, skip the missed dose. Do not take a double dose to make up for the missed doses.

If you interrupt Jalra treatment

Do not stop taking Jalra unless your doctor tells you to. If you have doubts about the duration of Jalra treatment, consult your doctor.

Like all medicines, this medicine can cause side effects, although not everyone will experience them.

Some symptoms require immediate medical attention

You should stop taking Jalra and see your doctor immediately if you experience any of the following side effects:

• Angioedema (rare: may affect up to 1 in 10,000 people): symptoms that include swollen face, tongue, or throat, difficulty swallowing, difficulty breathing, sudden appearance of hives or urticaria, which may be indicative of a reaction called “angioedema”.
• Liver disease (hepatitis) (unknown frequency): symptoms that include yellowing of the skin and eyes, nausea, loss of appetite, or dark-colored urine, which may be indicative of liver disease (hepatitis).
• Pancreatitis (inflammation of the pancreas) (rare: may affect up to 1 in 10,000 people): symptoms that include intense and persistent abdominal pain (stomach area), which can reach your back, as well as nausea and vomiting.

Other side effects

Some patients experienced the following side effects while taking Jalra:

• Very common (may affect more than 1 in 10 people): sore throat, nasal congestion, fever.
• Common (may affect up to 1 in 10 people): skin rash with itching, tremor, headache, dizziness, muscle pain, joint pain, constipation, swollen hands, ankles, or feet (edema), excessive sweating, vomiting, stomach pain and abdominal area (abdominal pain), diarrhea, heartburn, nausea (discomfort), blurred vision.
• Uncommon (may affect up to 1 in 100 people): weight gain, chills, weakness, sexual dysfunction, low blood glucose levels, flatulence.
• Rare (may affect up to 1 in 10,000 people): pancreatitis (inflammation of the pancreas).

Since the marketing of this product, the following side effects have also been reported:

• Unknown frequency (cannot be estimated from available data): localized skin peeling or blisters, inflammation of blood vessels (vasculitis) that may cause skin eruptions or flat, pointed, red, and rounded spots under the skin's surface or hematomas.

Reporting of side effects

If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the national notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.

• Keep this medication out of the sight and reach of children.
• Do not use this medication after the expiration date that appears on the blister pack and on the outer packaging after “EXP”/”CAD”. The expiration date is the last day of the month indicated.
• Store in the original packaging to protect it from moisture.
• Do not use Jalra if you observe that the packaging is damaged or shows signs of deterioration.
• Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. In this way, you will help protect the environment.

Composition of Jalra

• The active ingredient is vildagliptin.

Each tablet contains 50 mg of vildagliptin.

• The other components are anhydrous lactose, microcrystalline cellulose, sodium starch glycolate (type A) and magnesium stearate.

Appearance of the product and contents of the pack

Jalra 50 mg tablets are round, white to slightly yellowish, flat tablets with "NVR" on one face and "FB" on the other.

Jalra 50 mg tablets are available in packs containing 7, 14, 28, 30, 56, 60, 90, 112, 180 or 336 tablets and in multiple packs formed by 3 packs, each containing 112 tablets.

Only some pack sizes may be marketed.

Marketing Authorization Holder

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

Responsible Person

Lek d.d.

Verovskova ulica 57

Ljubljana 1526

Slovenia

Novartis Farmacéutica S.A.

Gran Via de les Corts Catalanes, 764

08013 Barcelona

Spain

Novartis Pharma GmbH

Roonstrasse 25

D-90429 Nuremberg

Germany

Novartis Pharmaceutical Manufacturing LLC

Verovskova ulica 57

Ljubljana 1000

Slovenia

Novartis Pharma GmbH

Sophie-Germain-Strasse 10

90443 Nürnberg

Germany

For further information about this medicinal product, please consult the representative of the marketing authorisation holder in your country:

Last update of the summary of product characteristics:

Other sources of information

The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu